Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.

Neuro-oncology - 1 Aug 2017

Hodges Tiffany R, Ott Martina, Xiu Joanne, Gatalica Zoran, Swensen Jeff, Zhou Shouhao, Huse Jason T, de Groot John, Li Shulin, Overwijk Willem W, Spetzler David, Heimberger Amy B

Abstract excerpt

BACKGROUND: Despite a multiplicity of clinical trials testing immune checkpoint inhibitors, the frequency of expression of potential predictive biomarkers is unknown in glioma. METHODS: In this study, we profiled the frequency of shared biomarker phenotypes. To clarify the relationships among tumor mutational load (TML), mismatch repair (MMR), and immune checkpoint expression, we profiled patients with glioma (n...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child, Preschool

Share to DNA Mismatch Repair

Share to Glioblastoma

Share to Glioma

Share to Lymphocytes, Tumor-Infiltrating

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 28371827
DOI: 10.1093/neuonc/nox026
PMCID: PMC5570198

Genes

MLH1
MSH2
MSH6
PMS2
IDH1
POLE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.PMID 28371827Read ↗

Mutational burden and immune recognition of gliomas.Semantic proximity Read ↗

Integrated pathway analysis identifies prognostically relevant subtypes of glioblastoma characterized by abnormalities in multi-omics.Semantic proximity Read ↗

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.Semantic proximity Read ↗

IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH-mutant astrocytoma PMMRDIA: a systematic review.Semantic proximity Read ↗

Hypermutation as a Potential Predictive Biomarker of Immunotherapy Efficacy in High-Grade Gliomas: A Broken Dream?Semantic proximity Read ↗

The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in GliomasSemantic proximity Read ↗

Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.Semantic proximity Read ↗

Comprehensive Molecular Analyses of a Novel Mutational Signature Classification System with Regard to Prognosis, Genomic Alterations, and Immune Landscape in GliomaSemantic proximity Read ↗

"De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.Semantic proximity Read ↗

Tumor Mutational Burden is Associated with Poor Outcomes in Diffuse Glioma.Semantic proximity Read ↗

Mechanisms and therapeutic implications of hypermutation in gliomas.Semantic proximity Read ↗

Immunogenetics of glioblastoma: the future of personalized patient managementSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.